| Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway KJ Kurppa, Y Liu, C To, T Zhang, M Fan, A Vajdi, EH Knelson, Y Xie, ... Cancer cell 37 (1), 104-122. e12, 2020 | 320 | 2020 |
| Single and dual targeting of mutant EGFR with an allosteric inhibitor C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ... Cancer discovery 9 (7), 926-943, 2019 | 243 | 2019 |
| Mutant‐selective allosteric EGFR degraders are effective against a broad range of drug‐resistant mutations J Jang, C To, DJH De Clercq, E Park, CM Ponthier, BH Shin, ... Angewandte Chemie 132 (34), 14589-14597, 2020 | 91 | 2020 |
| An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402-417, 2022 | 70 | 2022 |
| Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors DJH De Clercq, DE Heppner, C To, J Jang, E Park, CH Yun, ... ACS medicinal chemistry letters 10 (11), 1549-1553, 2019 | 58 | 2019 |
| Thiamine attenuates hypoxia-induced cell death in cultured neonatal rat cardiomyocytes BH Shin, SH Choi, EY Cho, MJ Shin, KC Hwang, HK Cho, JH Chung, ... Molecules and cells 18 (2), 133-140, 2004 | 41 | 2004 |
| Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 2019; 9: 926–943. doi: 10.1158/2159-8290 C To, J Jang, T Chen, E Park, M Mushajiang, DJH De Clercq, M Xu, ... CD-18-0903, 0 | 31 | |
| Design of a “two-in-one” mutant-selective epidermal growth factor receptor inhibitor that spans the orthosteric and allosteric sites F Wittlinger, DE Heppner, C To, M Günther, BH Shin, JK Rana, ... Journal of medicinal chemistry 65 (2), 1370-1383, 2021 | 18 | 2021 |
| Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC TW Gero, DE Heppner, TS Beyett, C To, SC Azevedo, J Jang, T Bunnell, ... Bioorganic & medicinal chemistry letters 68, 128718, 2022 | 11 | 2022 |
| Allosteric inhibition of drug resistant forms of EGFR L858R mutant NSCLC C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402, 2022 | 4 | 2022 |
| Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor F Wittlinger, DE Heppner, C To, M Guenther, BH Shin, JK Rana, ... | 2 | 2020 |
